GAN

Gigaxonin, encoded by GAN (KLHL16), is an E3 ubiquitin ligase adaptor that controls the turnover of cytoskeletal substrates and whose loss drives a neurodegenerative phenotype (PMID:16565160, PMID:27023907). Through its BTB, BACK, and KELCH repeat domains—the sites at which disease-causing mutations cluster—gigaxonin mediates homodimerization and substrate engagement to direct intermediate filament proteins toward ubiquitin-proteasome degradation (PMID:27023907). In knockout mice, loss of gigaxonin causes accumulation of microtubule-associated protein MAP8, which distorts the microtubule network, traps dynein in insoluble structures, and impairs axonal transport, producing vesicular accumulation and neuronal death (PMID:16565160). In patient iPSC-derived astrocytes and brain organoids, loss of gigaxonin produces dense perinuclear vimentin, GFAP, and neurofilament aggregates with abnormal nuclear morphology, with vimentin acting as an early effector of KLHL16 mutation and promoting GFAP oligomerization (PMID:37672338). Disease-associated GAN variants, including a splicing variant that skips exon 8 and disrupts the Kelch domain, link these mechanistic defects to human pathology (PMID:34889507).

1. 2006 High

   Established that gigaxonin loss causes substrate accumulation with direct cellular consequences, showing it functions in ubiquitin-proteasome-mediated degradation of a cytoskeletal target rather than merely correlating with disease.

   Evidence GAN knockout mouse with Western blot, immunofluorescence, in vitro axonal transport assays, and neuronal culture with MAP8 overexpression

   PMID:16565160

   Open questions at the time

   • Did not demonstrate direct ubiquitination of MAP8 by a gigaxonin-containing ligase in vitro
   • Mechanism by which MAP8 accumulation traps dynein not biochemically resolved
2. 2009 Low

   Connected gigaxonin expression to a peripheral neuropathy context, raising the possibility of regulated downregulation in acquired neuropathy.

   Evidence Whole-genome microarray with qPCR and Western blot validation in mouse spinal dorsal horn after NRTI treatment

   PMID:19398414

   Open questions at the time

   • Expression-level correlation only with no mechanistic follow-up
   • Causal role of gigaxonin downregulation in neuropathy not tested
3. 2016 Medium

   Mapped disease-causing mutations to the BTB, BACK, and KELCH domains, framing gigaxonin as an adaptor whose dimerization and substrate-binding surfaces are functionally critical for intermediate filament processing.

   Evidence Review and domain mapping integrating mutation databases with structural domain considerations

   PMID:27023907

   Open questions at the time

   • Domain-function assignments inferred, not from direct biochemical reconstitution
   • Substrate selectivity of each domain not experimentally dissected
4. 2021 Medium

   Provided direct molecular validation that a clinical GAN variant disrupts the Kelch domain, linking a specific splicing defect to loss of the substrate-recognition module.

   Evidence Whole-exome sequencing with cDNA-level validation of exon 8 skipping in a patient

   PMID:34889507

   Open questions at the time

   • Single family with no downstream biochemical characterization
   • Functional consequence for substrate degradation not measured
5. 2023 High

   Demonstrated in a human cellular system that gigaxonin loss broadly dysregulates intermediate filaments, identifying vimentin as an early effector that promotes GFAP aggregation and nuclear abnormalities.

   Evidence Patient iPSC-derived astrocytes, NPCs, and brain organoids with CRISPR isogenic controls, immunofluorescence, and overexpression systems

   PMID:37672338

   Open questions at the time

   • Direct ubiquitination of vimentin/GFAP by gigaxonin not shown in this system
   • Mechanism linking vimentin aggregation to nuclear KLHL16 mRNA accumulation unresolved

• How gigaxonin assembles into a functional E3 ligase complex and directly ubiquitinates each intermediate filament substrate remains biochemically uncharacterized in the available corpus.
• No reconstituted ubiquitination assay defining the gigaxonin ligase complex
• Substrate hierarchy and selectivity across MAP8, vimentin, GFAP, and neurofilaments not established